Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Conditions:   Cervical Carcinoma;   Esophageal Carcinoma;   Mucosal Melanoma;   Mucosal Melanoma of the Head and Neck;   Oral Cavity Mucosal Melanoma;   Recurrent Melanoma;   Stage II Vulvar Cancer;   Stage III Vulvar Cancer;   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IV Oral Cavity Cancer AJCC v6 and v7;   Stage IV Vulvar Cancer;   Stage IVA Oral Cavity Cancer AJCC v6 and v7;   Stage IVB Oral Cavity Cancer AJCC v6 and v7;   Stage IVC Oral Cavity Cancer AJCC v6 and v7;   Vaginal Carcinoma
Interventions:   Procedure: Conventional Surgery;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Patient Observation;   Radiation: Radiation Therapy
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified July 2017

http://ift.tt/2uvhqfa